Point72 Asset Management
ALGS icon

Point72 Asset Management’s Aligos Therapeutics ALGS Stock Holding History

Point72 Asset Management’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10
Closed -$216 – 2127
2023
Q1 		$216 Sell
10
-36,226
-100% -$1.38M ﹤0.01% 2151
2022
Q4 		$863K Sell
36,236
-445
-1% -$11.2K ﹤0.01% 1072
2022
Q3 		$1.01M Buy
36,681
+4,681
+15% +$155K ﹤0.01% 1055
2022
Q2 		$968K Hold
32,000
– – ﹤0.01% 1084
2022
Q1 		$1.72M Buy
32,000
+27,580
+624% +$2.21M 0.01% 894
2021
Q4 		$1.31M Buy
4,420
+528
+14% +$193K 0.01% 873
2021
Q3 		$1.51M Buy
+3,892
New +$1.54M 0.01% 814

Other funds holding ALGS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Point72 Asset Management's ALGS Position: Q2 2023 in Review

Point72 Asset Management sold out of Aligos Therapeutics (ALGS) in Q2 2023, closing a stake of 10 shares — an estimated $216 sold.

Point72 Asset Management first reported a position in ALGS in Q3 2021 and held it in 7 quarters. The position peaked at $1.72M in Q1 2022. 41 funds tracked by Wall St. Rank hold ALGS as of Q2 2023.

  • Point72 Asset Management reported no remaining Aligos Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Point72 Asset Management sold 10 Aligos Therapeutics shares in Q2 2023, an estimated $216.
  • Point72 Asset Management first reported a position in Aligos Therapeutics in Q3 2021 and held it in 7 quarters.
  • Point72 Asset Management's Aligos Therapeutics position peaked at $1.72M in Q1 2022.
  • 41 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2023.

Based on Point72 Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.